SEOUL, South Korea & PALO ALTO, Calif.--(BUSINESS WIRE)--HanAll BioPharma Co., Ltd. (HanAll), a public Korean biopharmaceutical company and leader in development of novel biologics and new chemical entities in immunology and oncology, and Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic animals for the discovery of human therapeutic antibodies, today announced an alliance that provides HanAll with a license to use OMT’s OmniRat®, OmniMouse® and OmniFlic® platform for the generation of novel human antibodies against the Neonatal Fc Receptor (FcRn) and other undisclosed target antigens.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
